Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Chemoresistance and genetic mutations in hepatocellular carcinoma: a pharmacogenomic atlas of 51 patients.

BMC cancer - 28 Mar 2026

Jiang Hong-Han, Feng Guo-Ying, Shi Yuan, Li Xiao-Dong, Zhang Yi-Zhou, Cheng Yu, Shi Zheng-Rong

Abstract excerpt

BACKGROUND: Chemoresistance remains a major barrier in hepatocellular carcinoma (HCC) treatment, and research on personalized therapies for resistant patients is still nascent. This study aimed to construct a preliminary gene-drug resistance map for HCC to advance research in personalized treatment. PATIENTS AND METHODS: Tumor tissues from 51 HCC patients who underwent surgical resection at the First Affiliated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Hepatocellular

Share to DNA-Binding Proteins

Share to Drug Resistance, Neoplasm

Share to Exome Sequencing

Share to Liver Neoplasms

Share to Neoplasm Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 41904394
DOI: 10.1186/s12885-026-15621-2
PMCID: PMC13154435

Genes

ADM
FAT4
KMT2D
PABPC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Chemoresistance and genetic mutations in hepatocellular carcinoma: a pharmacogenomic atlas of 51 patients.PMID 41904394Read ↗

TP53 /KRAS Co-Mutations Create Divergent Prognosis Signatures in Intrahepatic CholangiocarcinomaSemantic proximity Read ↗

Mutation profile and its correlation with clinicopathology in Chinese hepatocellular carcinoma patientsSemantic proximity Read ↗

Impact of tumor suppressor genes inactivation on the multidrug resistance phenotype of hepatocellular carcinoma cells.Semantic proximity Read ↗

Resistance patterns in drug-adapted cancer cell lines reflect the complex evolution in clinical tumoursSemantic proximity Read ↗

Integrating Genomics Into Clinical Practice in Hepatocellular Carcinoma: The Challenges AheadSemantic proximity Read ↗

Sorafenib Resistance in Hepatocellular Carcinoma: The Relevance of Genetic HeterogeneitySemantic proximity Read ↗

ARID1A Mutation from Targeted Next-Generation Sequencing Predicts Primary Resistance to Gemcitabine and Cisplatin Chemotherapy in Advanced Biliary Tract Cancer.Semantic proximity Read ↗

Whole-exome sequencing reveals potential mechanisms of drug resistance to FGFR3-TACC3 targeted therapy and subsequent drug selection: towards a personalized medicine.Semantic proximity Read ↗

Drug Resistance in NSCLC is Associated with Tumor Micro-environmentSemantic proximity Read ↗

Alterations in DNA Damage Repair Genes in Primary Liver CancerSemantic proximity Read ↗

Integrative analysis of multi-omics data reveals inhibition of RB1 signaling promotes apatinib resistance of hepatocellular carcinomaSemantic proximity Read ↗

Mechanisms of drug resistance in hepatocellular carcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.